| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Defibrillators, Implantable | 20 | 2024 | 226 | 2.870 |
Why?
|
| Death, Sudden, Cardiac | 18 | 2024 | 246 | 2.660 |
Why?
|
| Long QT Syndrome | 11 | 2024 | 110 | 1.750 |
Why?
|
| Catheter Ablation | 13 | 2022 | 575 | 1.630 |
Why?
|
| Heart Defects, Congenital | 19 | 2022 | 1795 | 1.570 |
Why?
|
| Pacemaker, Artificial | 7 | 2022 | 206 | 1.400 |
Why?
|
| Electrocardiography | 23 | 2024 | 1154 | 1.390 |
Why?
|
| Cardiomyopathy, Hypertrophic | 6 | 2024 | 169 | 1.370 |
Why?
|
| Arrhythmias, Cardiac | 13 | 2022 | 506 | 1.270 |
Why?
|
| Heart Conduction System | 9 | 2024 | 161 | 1.070 |
Why?
|
| Tachycardia, Supraventricular | 6 | 2022 | 106 | 1.010 |
Why?
|
| Sports | 2 | 2024 | 72 | 1.010 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 3 | 2022 | 22 | 0.970 |
Why?
|
| Fontan Procedure | 4 | 2021 | 181 | 0.840 |
Why?
|
| Ebstein Anomaly | 5 | 2022 | 26 | 0.780 |
Why?
|
| Wolff-Parkinson-White Syndrome | 6 | 2020 | 74 | 0.760 |
Why?
|
| Tachycardia, Ectopic Junctional | 2 | 2011 | 13 | 0.690 |
Why?
|
| Tachycardia, Ventricular | 5 | 2021 | 202 | 0.680 |
Why?
|
| Cardiac Pacing, Artificial | 5 | 2017 | 115 | 0.680 |
Why?
|
| Electric Countershock | 6 | 2024 | 72 | 0.660 |
Why?
|
| Child | 67 | 2024 | 30559 | 0.660 |
Why?
|
| Cryosurgery | 3 | 2022 | 196 | 0.640 |
Why?
|
| Tachycardia | 3 | 2016 | 84 | 0.620 |
Why?
|
| Bradycardia | 2 | 2016 | 73 | 0.590 |
Why?
|
| Adolescent | 51 | 2024 | 32767 | 0.560 |
Why?
|
| Pericardium | 4 | 2021 | 146 | 0.550 |
Why?
|
| Heart Rate | 3 | 2024 | 742 | 0.550 |
Why?
|
| Sinus of Valsalva | 1 | 2016 | 35 | 0.540 |
Why?
|
| Thoracotomy | 2 | 2016 | 218 | 0.540 |
Why?
|
| Exercise Test | 4 | 2020 | 310 | 0.540 |
Why?
|
| Heart Diseases | 5 | 2018 | 724 | 0.530 |
Why?
|
| Anti-Arrhythmia Agents | 6 | 2021 | 236 | 0.490 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 242 | 0.460 |
Why?
|
| Heart Valves | 1 | 2014 | 60 | 0.460 |
Why?
|
| Postoperative Complications | 9 | 2018 | 5681 | 0.440 |
Why?
|
| Retrospective Studies | 44 | 2024 | 39890 | 0.430 |
Why?
|
| Atrial Fibrillation | 5 | 2020 | 730 | 0.430 |
Why?
|
| Child, Preschool | 28 | 2024 | 17061 | 0.420 |
Why?
|
| Cardiology | 4 | 2021 | 511 | 0.410 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2012 | 42 | 0.410 |
Why?
|
| Atrioventricular Block | 1 | 2012 | 40 | 0.400 |
Why?
|
| Magnetics | 1 | 2012 | 98 | 0.400 |
Why?
|
| Cardiac Electrophysiology | 3 | 2021 | 11 | 0.380 |
Why?
|
| Chest Pain | 1 | 2012 | 173 | 0.380 |
Why?
|
| Athletes | 3 | 2024 | 60 | 0.380 |
Why?
|
| Urologic Surgical Procedures | 1 | 2011 | 93 | 0.370 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2010 | 15 | 0.370 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2020 | 71 | 0.370 |
Why?
|
| Atenolol | 1 | 2010 | 45 | 0.370 |
Why?
|
| Survivors | 1 | 2016 | 1021 | 0.360 |
Why?
|
| Treatment Outcome | 29 | 2024 | 33737 | 0.360 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 450 | 0.350 |
Why?
|
| Male | 58 | 2024 | 128315 | 0.350 |
Why?
|
| Humans | 88 | 2024 | 270740 | 0.340 |
Why?
|
| Minnesota | 7 | 2018 | 126 | 0.340 |
Why?
|
| Heart | 5 | 2022 | 1195 | 0.340 |
Why?
|
| Prosthesis Failure | 3 | 2017 | 198 | 0.330 |
Why?
|
| Mass Screening | 4 | 2021 | 1552 | 0.320 |
Why?
|
| Young Adult | 23 | 2024 | 22251 | 0.310 |
Why?
|
| Infant | 20 | 2024 | 13999 | 0.310 |
Why?
|
| American Heart Association | 5 | 2021 | 287 | 0.300 |
Why?
|
| Abnormalities, Multiple | 1 | 2014 | 1023 | 0.300 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2007 | 30 | 0.300 |
Why?
|
| Tricuspid Valve | 2 | 2018 | 64 | 0.290 |
Why?
|
| Female | 58 | 2024 | 148940 | 0.290 |
Why?
|
| Cardiac Surgical Procedures | 4 | 2023 | 1158 | 0.290 |
Why?
|
| Device Removal | 4 | 2021 | 339 | 0.290 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2018 | 230 | 0.290 |
Why?
|
| Prostheses and Implants | 2 | 2019 | 294 | 0.280 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2008 | 128 | 0.280 |
Why?
|
| Endocarditis, Bacterial | 1 | 2008 | 152 | 0.280 |
Why?
|
| Heart Transplantation | 3 | 2017 | 897 | 0.270 |
Why?
|
| Electrodes, Implanted | 2 | 2021 | 185 | 0.260 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2007 | 264 | 0.260 |
Why?
|
| Tachycardia, Reciprocating | 2 | 2016 | 3 | 0.250 |
Why?
|
| Vascular Resistance | 2 | 2005 | 213 | 0.250 |
Why?
|
| Atrial Flutter | 2 | 2016 | 34 | 0.250 |
Why?
|
| Accessory Atrioventricular Bundle | 2 | 2017 | 8 | 0.250 |
Why?
|
| Parents | 1 | 2012 | 1082 | 0.250 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2007 | 296 | 0.240 |
Why?
|
| Mitral Valve Prolapse | 2 | 2016 | 30 | 0.240 |
Why?
|
| Heart Ventricles | 3 | 2021 | 847 | 0.240 |
Why?
|
| Electronics | 5 | 2022 | 62 | 0.240 |
Why?
|
| Cardiac Catheterization | 2 | 2006 | 669 | 0.240 |
Why?
|
| Nitric Oxide | 2 | 2005 | 658 | 0.230 |
Why?
|
| Risk Factors | 16 | 2024 | 17888 | 0.230 |
Why?
|
| Cardiac Conduction System Disease | 2 | 2021 | 16 | 0.230 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 879 | 0.220 |
Why?
|
| Heart Atria | 4 | 2020 | 354 | 0.220 |
Why?
|
| Bronchodilator Agents | 1 | 2005 | 225 | 0.220 |
Why?
|
| Subclavian Vein | 2 | 2017 | 44 | 0.220 |
Why?
|
| Hypertension, Pulmonary | 2 | 2005 | 464 | 0.210 |
Why?
|
| Consensus | 5 | 2021 | 1106 | 0.210 |
Why?
|
| Time Factors | 10 | 2024 | 13006 | 0.210 |
Why?
|
| Adult | 28 | 2024 | 82040 | 0.210 |
Why?
|
| Staphylococcal Infections | 1 | 2008 | 678 | 0.200 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2023 | 89 | 0.200 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2015 | 100 | 0.200 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 3 | 2018 | 60 | 0.200 |
Why?
|
| Predictive Value of Tests | 3 | 2024 | 4960 | 0.200 |
Why?
|
| Vena Cava, Superior | 2 | 2016 | 78 | 0.200 |
Why?
|
| Oxygen | 2 | 2005 | 791 | 0.190 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2021 | 20 | 0.190 |
Why?
|
| Plasminogen Activators | 1 | 2001 | 55 | 0.190 |
Why?
|
| United States Food and Drug Administration | 2 | 2022 | 323 | 0.190 |
Why?
|
| Lidocaine | 1 | 2021 | 81 | 0.190 |
Why?
|
| Electric Impedance | 1 | 2021 | 101 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2015 | 315 | 0.190 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2021 | 66 | 0.190 |
Why?
|
| Action Potentials | 1 | 2024 | 588 | 0.180 |
Why?
|
| Ventricular Fibrillation | 2 | 2022 | 59 | 0.180 |
Why?
|
| Incidence | 8 | 2020 | 5824 | 0.180 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2001 | 161 | 0.170 |
Why?
|
| Medical Records | 3 | 2016 | 442 | 0.170 |
Why?
|
| Device Approval | 1 | 2018 | 18 | 0.160 |
Why?
|
| Thyrotropin | 1 | 2019 | 124 | 0.160 |
Why?
|
| Amiodarone | 1 | 2019 | 51 | 0.160 |
Why?
|
| Electrophysiology | 2 | 2022 | 350 | 0.160 |
Why?
|
| Health Policy | 1 | 2021 | 278 | 0.160 |
Why?
|
| Esthetics | 1 | 2018 | 116 | 0.150 |
Why?
|
| Exercise | 2 | 2024 | 1184 | 0.150 |
Why?
|
| Glucocorticoids | 1 | 2021 | 617 | 0.150 |
Why?
|
| Coronary Artery Disease | 2 | 2008 | 884 | 0.150 |
Why?
|
| Recurrence | 4 | 2018 | 4878 | 0.150 |
Why?
|
| Subcutaneous Tissue | 1 | 2017 | 57 | 0.150 |
Why?
|
| Death, Sudden | 1 | 2017 | 56 | 0.150 |
Why?
|
| Ventricular Septum | 1 | 2017 | 17 | 0.150 |
Why?
|
| Follow-Up Studies | 13 | 2024 | 15218 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 402 | 0.140 |
Why?
|
| Ventricular Dysfunction | 1 | 2017 | 33 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2019 | 206 | 0.140 |
Why?
|
| Cicatrix | 1 | 2018 | 187 | 0.140 |
Why?
|
| Surveys and Questionnaires | 7 | 2022 | 5923 | 0.140 |
Why?
|
| United States | 13 | 2022 | 15861 | 0.140 |
Why?
|
| Thyroid Gland | 1 | 2019 | 366 | 0.140 |
Why?
|
| Arterial Switch Operation | 1 | 2016 | 22 | 0.140 |
Why?
|
| Heart Septum | 2 | 2023 | 60 | 0.130 |
Why?
|
| Echocardiography | 4 | 2018 | 1228 | 0.130 |
Why?
|
| Medical Overuse | 1 | 2015 | 51 | 0.130 |
Why?
|
| Ketosis | 1 | 2015 | 15 | 0.130 |
Why?
|
| Vena Cava, Inferior | 1 | 2016 | 194 | 0.130 |
Why?
|
| Transposition of Great Vessels | 1 | 2016 | 133 | 0.130 |
Why?
|
| Coitus | 1 | 2015 | 24 | 0.120 |
Why?
|
| Ventricular Function, Right | 1 | 2016 | 116 | 0.120 |
Why?
|
| Risk Assessment | 4 | 2024 | 6764 | 0.120 |
Why?
|
| Defibrillators | 1 | 2015 | 27 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2021 | 831 | 0.120 |
Why?
|
| Pulmonary Veins | 1 | 2016 | 181 | 0.120 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 289 | 0.120 |
Why?
|
| Hypoglycemia | 1 | 2015 | 220 | 0.110 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2016 | 509 | 0.110 |
Why?
|
| Stroke | 1 | 2001 | 1049 | 0.110 |
Why?
|
| Forecasting | 1 | 2015 | 702 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 564 | 0.100 |
Why?
|
| Angina Pectoris | 1 | 2012 | 67 | 0.100 |
Why?
|
| Regeneration | 1 | 2015 | 284 | 0.100 |
Why?
|
| Energy Drinks | 1 | 2011 | 4 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2015 | 714 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2015 | 501 | 0.100 |
Why?
|
| Age Factors | 6 | 2024 | 5457 | 0.100 |
Why?
|
| Texas | 6 | 2012 | 6449 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 6256 | 0.100 |
Why?
|
| Fluoroscopy | 1 | 2012 | 223 | 0.100 |
Why?
|
| Sotalol | 1 | 2011 | 34 | 0.090 |
Why?
|
| Catheters | 1 | 2012 | 133 | 0.090 |
Why?
|
| Caffeine | 1 | 2011 | 96 | 0.090 |
Why?
|
| Kidney Pelvis | 1 | 2011 | 114 | 0.090 |
Why?
|
| Quality of Life | 2 | 2018 | 4761 | 0.090 |
Why?
|
| Endovascular Procedures | 1 | 2016 | 471 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2015 | 1269 | 0.090 |
Why?
|
| Heart Failure | 2 | 2017 | 2330 | 0.090 |
Why?
|
| Stents | 1 | 2016 | 999 | 0.090 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2009 | 6 | 0.090 |
Why?
|
| Muscular Dystrophies | 1 | 2010 | 62 | 0.090 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 146 | 0.090 |
Why?
|
| Disease-Free Survival | 3 | 2016 | 10265 | 0.090 |
Why?
|
| DNA | 1 | 2018 | 3050 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2017 | 914 | 0.090 |
Why?
|
| Societies, Medical | 1 | 2016 | 1320 | 0.080 |
Why?
|
| Middle Aged | 16 | 2024 | 90352 | 0.080 |
Why?
|
| Infant, Newborn | 8 | 2021 | 8699 | 0.080 |
Why?
|
| Cardiomyopathies | 3 | 2014 | 552 | 0.080 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 193 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 1312 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2024 | 13414 | 0.080 |
Why?
|
| Mitral Valve Stenosis | 1 | 2008 | 43 | 0.080 |
Why?
|
| Canada | 3 | 2014 | 440 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 240 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2012 | 591 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5101 | 0.070 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 799 | 0.070 |
Why?
|
| Registries | 2 | 2013 | 2211 | 0.070 |
Why?
|
| Heart Block | 1 | 2007 | 45 | 0.070 |
Why?
|
| Coronary Vessels | 1 | 2011 | 626 | 0.070 |
Why?
|
| Administration, Inhalation | 2 | 2005 | 300 | 0.070 |
Why?
|
| Procainamide | 1 | 2006 | 11 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2012 | 931 | 0.070 |
Why?
|
| Ventricular Function | 1 | 2007 | 100 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 5776 | 0.070 |
Why?
|
| Shock, Septic | 1 | 2008 | 188 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2019 | 313 | 0.070 |
Why?
|
| Constriction, Pathologic | 1 | 2006 | 322 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 2224 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2011 | 5056 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2008 | 1933 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2005 | 418 | 0.060 |
Why?
|
| Equipment Failure | 2 | 2015 | 191 | 0.060 |
Why?
|
| Mutation | 3 | 2020 | 15912 | 0.050 |
Why?
|
| International Cooperation | 2 | 2016 | 325 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2021 | 1437 | 0.050 |
Why?
|
| Acute Disease | 1 | 2008 | 2493 | 0.050 |
Why?
|
| Return to Sport | 1 | 2022 | 4 | 0.050 |
Why?
|
| Down Syndrome | 1 | 2005 | 227 | 0.050 |
Why?
|
| Survival Rate | 4 | 2020 | 12541 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2011 | 1302 | 0.050 |
Why?
|
| Reoperation | 2 | 2018 | 1392 | 0.050 |
Why?
|
| Iatrogenic Disease | 1 | 2023 | 195 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2005 | 521 | 0.050 |
Why?
|
| Bereavement | 1 | 2021 | 32 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2021 | 1696 | 0.050 |
Why?
|
| Latin America | 1 | 2021 | 127 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2020 | 9470 | 0.040 |
Why?
|
| Equipment Design | 1 | 2024 | 1197 | 0.040 |
Why?
|
| Functional Laterality | 1 | 2001 | 274 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2021 | 102 | 0.040 |
Why?
|
| LIM Domain Proteins | 1 | 2020 | 103 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 2345 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2019 | 31 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2021 | 231 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 311 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2001 | 269 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1568 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2019 | 38 | 0.040 |
Why?
|
| Ankyrins | 1 | 2020 | 109 | 0.040 |
Why?
|
| Pregnancy | 1 | 2012 | 8130 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 230 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2018 | 48 | 0.040 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2018 | 60 | 0.040 |
Why?
|
| Atrial Function, Right | 1 | 2018 | 9 | 0.040 |
Why?
|
| Atrial Function, Left | 1 | 2018 | 28 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2018 | 196 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2018 | 103 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 160 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 522 | 0.040 |
Why?
|
| Oregon | 1 | 2017 | 15 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 927 | 0.040 |
Why?
|
| Cardiomegaly | 1 | 2018 | 180 | 0.040 |
Why?
|
| Family | 1 | 2021 | 783 | 0.040 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2021 | 347 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 247 | 0.030 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2016 | 66 | 0.030 |
Why?
|
| Brugada Syndrome | 1 | 2016 | 20 | 0.030 |
Why?
|
| Echocardiography, Doppler | 1 | 2016 | 187 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 448 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 1099 | 0.030 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2015 | 9 | 0.030 |
Why?
|
| Nadolol | 1 | 2015 | 36 | 0.030 |
Why?
|
| School Health Services | 1 | 2016 | 112 | 0.030 |
Why?
|
| Angiography | 1 | 2016 | 350 | 0.030 |
Why?
|
| Global Health | 1 | 2020 | 692 | 0.030 |
Why?
|
| Atrial Function | 1 | 2014 | 15 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 1125 | 0.030 |
Why?
|
| Propranolol | 1 | 2015 | 157 | 0.030 |
Why?
|
| Remission, Spontaneous | 1 | 2014 | 125 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 533 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 658 | 0.030 |
Why?
|
| Pedigree | 1 | 2018 | 2042 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 697 | 0.030 |
Why?
|
| Aged | 5 | 2018 | 73333 | 0.030 |
Why?
|
| Pediatric Assistants | 1 | 2013 | 1 | 0.030 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 1174 | 0.030 |
Why?
|
| Patient Safety | 1 | 2018 | 613 | 0.030 |
Why?
|
| Prognosis | 3 | 2018 | 22505 | 0.030 |
Why?
|
| Syndrome | 1 | 2016 | 1407 | 0.030 |
Why?
|
| Polytetrafluoroethylene | 1 | 2013 | 109 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 686 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2016 | 681 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2357 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2018 | 3584 | 0.030 |
Why?
|
| Financing, Government | 1 | 2012 | 37 | 0.030 |
Why?
|
| State Government | 1 | 2012 | 33 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2020 | 2098 | 0.020 |
Why?
|
| Benchmarking | 1 | 2013 | 275 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2011 | 55 | 0.020 |
Why?
|
| Sick Role | 1 | 2011 | 72 | 0.020 |
Why?
|
| Physical Examination | 1 | 2012 | 305 | 0.020 |
Why?
|
| Swine | 1 | 2015 | 1607 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2018 | 5694 | 0.020 |
Why?
|
| Algorithms | 2 | 2013 | 3891 | 0.020 |
Why?
|
| Students | 1 | 2012 | 333 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 113 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2011 | 533 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2016 | 2250 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4492 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2009 | 322 | 0.020 |
Why?
|
| Hypotension | 1 | 2009 | 232 | 0.020 |
Why?
|
| Acecainide | 1 | 2006 | 3 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 5002 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2009 | 9292 | 0.020 |
Why?
|
| Time | 1 | 2007 | 183 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 242 | 0.020 |
Why?
|
| Tetralogy of Fallot | 1 | 2008 | 164 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3404 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2020 | 5438 | 0.020 |
Why?
|
| Psychometrics | 1 | 2011 | 973 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2012 | 2828 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 4328 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 2184 | 0.020 |
Why?
|
| Creatinine | 1 | 2006 | 529 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1571 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 7895 | 0.010 |
Why?
|
| Gestational Age | 1 | 2006 | 1173 | 0.010 |
Why?
|
| Pulmonary Circulation | 1 | 2002 | 132 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 7381 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 4372 | 0.010 |
Why?
|
| Hemodynamics | 1 | 2002 | 949 | 0.010 |
Why?
|
| Disease Progression | 1 | 2009 | 6867 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 5162 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 61956 | 0.010 |
Why?
|